Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02746952 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia
A Phase 1 study, sponsored by Institut de Recherches Internationales Servier.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02746952 is a Phase 1 study that has completed, run by Institut de Recherches Internationales Servier. The registered enrollment target is 25 participants.
The verdict
NCT02746952, a Phase 1 study, has completed, sponsored by Institut de Recherches Internationales Servier.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The study is in two parts: a dose escalation then a safety dose expansion. The purpose of the dose escalation part is to evaluate the safety and tolerability of ascending doses of UCART19 (dose-escalation part) given as a single infusion in patients with relapsed / refractory (R/R) B-cell acute lymphoblastic leukaemia (B-ALL), to determine the maximum tolerated dose (MTD), the recommended dose and the lymphodepletion regimen. The purpose of the safety dose expansion is to assess the safety and tolerability of the RD for UCART19.
Interventions
- BIOLOGICAL UCART19
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-08-01 |
| Est. Completion | 2020-07-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02746952
The ClinicalTrials.gov registry entry for NCT02746952 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institut de Recherches Internationales Servier, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which UCART19 is the first listed.
NCT02746952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02746952 about?
NCT02746952 is a clinical study titled "Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia". The study is in two parts: a dose escalation then a safety dose expansion. The purpose of the dose escalation part is to evaluate the safety and tolerability of ascending doses of UCART19 (dose-escalation part) given as a single infusion in patients with relapsed / refractory (R/R) B-cell acute lymp...
What is the current status of trial NCT02746952?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2016-08-01. Estimated completion is 2020-07-28.
What interventions are being tested in trial NCT02746952?
The interventions under investigation include: UCART19 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02746952?
This trial is sponsored by Institut de Recherches Internationales Servier, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.